Cencora reported fiscal third-quarter results on August 5, with revenue up 5.1% to $84.8 billion and adjusted earnings per share up 12.0% to $4.48, while management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion of its own stock during the quarter, completing in one quarter the buybacks it had expected to finish by the close of calendar 2026, and the board declared a $0.60 quarterly dividend payable August 31 to holders of record on August 14. Adjusted operating income rose 17.0% while revenue grew only 5.1%, helped by adjusted gross profit that jumped 23.2% as adjusted gross margin widened 61 basis points to 4.16%, with the February OneOncology acquisition lifting margins in the US business. US Healthcare Solutions grew operating income 15.9%, while International Healthcare Solutions operating income rose 20.8%. Adjusted operating expenses jumped 26.8% because OneOncology brought expenses along with its profits, net interest expense rose $58.9 million from a year earlier, and lower-margin GLP-1 drugs plus an oncology customer lost in 2025 and lower sales to a large mail order customer weighed on US revenue.
Cencora Inc.Cencora raised full-year adjusted EPS guidance to $17.75-$17.95 and completed a $1B buyback, with Q3 adjusted EPS up 12%.
The February OneOncology acquisition lifted margins in Cencora's US business, though it also brought added operating expenses.
